Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suramin sodium

Drug Profile

Suramin sodium

Alternative Names: Antrypol; Bayer 205; CI 1003; Germanin; Metaret; Moranyl; Suramin; Suramin hexasodium

Latest Information Update: 22 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer Austrian Academy of Sciences; Bayer; National Cancer Institute (USA); Optimum Therapeutics; Pfizer; The First Affiliated Hospital of Zhengzhou University; University of California, San Diego; University of Wisconsin-Madison
  • Class Antiprotozoals; Naphthalenesulfonates
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Intercellular signalling peptide and protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Pervasive child development disorders
  • Phase I Enterovirus A infections
  • Discontinued Atherosclerosis; Bladder cancer; Breast cancer; Cancer pain; HIV infections; Prostate cancer; Vascular restenosis

Most Recent Events

  • 19 Dec 2018 Phase-I clinical trials in Enterovirus A infections (In volunteers) in China (IV) (NCT03804749)
  • 24 Jun 2018 Biomarkers information updated
  • 01 May 2015 Phase-I/II clinical trials in Pervasive child development disorders in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top